This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holtz, M. Articles by Bhatia, R. Search for Related Content PubMed PubMed Citation Articles by Holtz, M. Articles by Bhatia, R.

Growth Factor Stimulation Reduces Residual Quiescent Chronic Myelogenous Leukemia Progenitors Remaining after Imatinib Treatment

Division of Hematology and Hematopoietic Cell Transplantation, Department of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California

Requests for reprints: Ravi Bhatia, Division of Hematology and Bone Marrow Transplantation, Department of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010. Phone: 626-359-8111, ext. 63610; Fax: 626-301-8973; E-mail: rbhatia{at}coh.org.

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of chronic myelogenous leukemia (CML) but fails to eliminate all leukemia cells. Residual leukemia stem and progenitor cells persist in imatinib-responsive patients and may be a potential source of relapse. Previous studies indicate that imatinib preferentially targets dividing cells, and nondividing progenitor cells are resistant to imatinib-mediated apoptosis. We investigated whether growth factor stimulation of progenitor proliferation could reduce the number of residual nondividing cells remaining after imatinib treatment. CML and normal CD34⁺ cells were labeled with 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester (CFSE) to track cell division and cultured in low or high concentrations of growth factor to determine effects of growth factor stimulation on nondividing cells. High growth factor concentrations significantly enhanced CML proliferation with or without imatinib treatment and significantly reduced the number of viable, nondividing CFSE bright cells remaining after imatinib exposure. Stimulation with high growth factor before imatinib treatment further reduced the number of residual nondividing CML CD34⁺ cells. Importantly, clinically achievable concentrations of granulocyte macrophage colony-stimulating factor alone or in combination with granulocyte colony-stimulating factor also significantly reduced nondividing CML CD34⁺ cells. These results support the potential efficacy of growth factor stimulation in reducing the residual leukemia progenitor population in imatinib-treated patients. [Cancer Res 2007;67(3):1113–20]

This article has been cited by other articles:

				J. McLaughlin, D. Cheng, O. Singer, R. U. Lukacs, C. G. Radu, I. M. Verma, and O. N. Witte Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics PNAS, December 18, 2007; 104(51): 20501 - 20506. [Abstract] [Full Text] [PDF]